Microba Life Sciences

Microba Life Sciences is a precision microbiome company headquartered in Brisbane, Australia, that specializes in the analysis and therapeutic application of the human gut microbiome. By leveraging proprietary metagenomics technology, the company provides high-resolution diagnostic testing services and conducts advanced research into microbiome-derived therapeutics for conditions such as inflammatory bowel disease and autoimmune disorders. Listed on the Australian Securities Exchange (ASX: MAP), Microba integrates clinical-grade diagnostics with a robust data-driven discovery platform to bridge the gap between microbiome research and clinical practice. The company operates at the intersection of biotechnology and data science, utilizing a sophisticated pipeline to identify microbial signatures linked to human health. Through its international expansion and the integration of its testing and supplement divisions, Microba aims to provide actionable insights into the microbiome. By collaborating with global research organizations and clinicians, the company continues to advance its mission of harnessing the potential of the microbiome to improve patient outcomes and drive innovation in personalized medicine.

Microba’s mission is to advance society by harnessing the profound potential of the microbiome.

• Developed a world-leading proprietary metagenomic sequencing and analysis platform.
• Successfully listed on the Australian Securities Exchange (ASX: MAP).
• Expanded commercial operations across Australia, the UK, Europe, the US, and New Zealand.
• Validated clinical diagnostic tools like MetaPanel for gastrointestinal condition identification.

Sources

• Microba Official Website
• Microba Investor Hub
• ASX Company Announcements